Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

ive findings. However, there is much value we can bring to patients through our Staccato technology, as evidenced by our late-stage, pre-NDA program with AZ-004 (Staccato loxapine, high dose) for the acute treatment of agitation."

AZ-104 Phase 2b Clinical Trial Design

The AZ-104 Phase 2b clinical trial was an outpatient, multi-center, randomized, double-blind, single administration, placebo-controlled study. The study was designed to evaluate the treatment of a single migraine attack of moderate to severe intensity in each of approximately 360 migraine patients, with or without aura. Two doses of AZ-104 (1.25 mg and 2.5 mg) and placebo were evaluated in the clinical trial. The study enrolled a total of 366 patients: 125 patients in the placebo dose group, 121 patients in the 1.25 mg dose group, and 120 patients in the 2.5 mg dose group.

Patients rated their headache pain using the International Headache Society (IHS) 4-point rating scale. The primary efficacy endpoint was headache pain relief (headache pain rated as mild or none) at 2 hours post-dose. Secondary efficacy endpoints for the clinical trial included various additional measurements of pain relief, as well as effects on nausea, vomiting, phonophobia and photophobia. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all analyses were made on an intent-to-treat basis. Safety evaluations were also made throughout the clinical trial period.

Primary Efficacy Endpoint

AZ-104 was numerically superior to placebo in pain-relief at 2-hours post-dose, but these differences were not statistically significant. Pain relief was observed in 56% of patients receiving the 2.5 mg dose (p=0.11) and 54% of patients receiving the 1.25 mg dose (p=0.12), as compared to 45% of patients receiving placebo.

Another commonly used measure of efficacy i
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Sept. 21, 2011 SmallCapVoice.com, Inc. announced ... Alarm Concepts Holding, Inc. (OTCQB: MDHI), manufacturer ... alarm system that allows the users to ... is now available. The interview can be ...
... organiser UBM Conferences , a division of UBM ... introduced CPhI Lunchtime Education Series to be hosted 25th ... Worldwide event which is focused on pharmaceutical ingredients. Organised ... workshop format with six interactive sessions over the three ...
Cached Medicine Technology:A New Audio Interview with Medical Alarm Concepts Holdings, Inc., CEO, Howard Teicher, is now at SmallCapVoice.com 2CPhI Conferences Introduces New Lunchtime Education Series 2
(Date:8/29/2014)... According to the latest review published by DailyGossip.org, this ... safely and naturally. The new method promises great efficiency in ... , Daily Gossip writes in its Flat Belly Forever ... how to eliminate the extra pounds, it will also show ... to body modeling. , The method reveals some breakthrough ...
(Date:8/29/2014)... The new review that can be read ... holistic system that will permanently eliminate the symptoms of this ... can achieve a cure in as fast as 30 to ... only about one week. , The Tinnitus Miracle review ... as mild hearing loss, pain in the ear and dizziness. ...
(Date:8/29/2014)... CO (PRWEB) August 29, 2014 Panic ... attack is the feeling of intense stress and fear, ... life of the sufferer, causing insecurity and affecting relationships. ... factors and there are many symptoms that patients can ... are among these symptoms. Overcoming panic attacks is extremely ...
(Date:8/29/2014)... Dr. Parsa Mohebi, founder of US ... practice to Parsa Mohebi Hair Restoration. Since officially launching ... of hair loss patients throughout Southern California. It even ... Los Angeles, Beverly Hills, and Orange County. These patients ... many of which Dr. Mohebi perfected through new technology ...
(Date:8/29/2014)... 29, 2014 According to a CNN ... Overdoses (8/25), a new study found that those ... have seen a significant decrease in the number of ... a ten year period, and comparing various states with ... find that there was about a 25% decrease in ...
Breaking Medicine News(10 mins):Health News:Flat Belly Forever Review Exposes the Way to Eliminate Body Fat Easily 2Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3
... as Titan of Business & ... ... Washington DC,business community leaders achieved extraordinary fundraising success on,Saturday ... guests,to the Washington Convention Center for one of DC,s largest ...
... Park Ridge, Ill. (April 3, 2008) Choline, an essential nutrient ... 24 percent reduced risk of breast cancer, according to a ... of Health (NIH), to be published in The FASEB Journals ... body of evidence that links egg consumption to a decreased ...
... like dementia are on the rise. And, thanks to ... will be at the forefront of research dealing with ... research teams have won National Health and Medical Research ... in hospitals, transitions to residential care and ascertaining the ...
... 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ) ... today announced that it entered into a three ... agreement with Sovereign,Business Capital ("SBC", formerly Business Alliance ... loan credit facility, SBC takes,assignment of TeamStaff,s prior ...
... Edwards,Lifesciences Corporation (NYSE: EW ), a global ... disease, today announced that,its chairman and chief executive ... trading plan under Rule 10b5-1 of the Securities ... similar plan that expired last,month., The new ...
... degree made attempt, but economic status also plays role ... that promote quitting smoking are more likely to have ... dangers of secondhand smoke have a similar effect on ... Wisconsin study. , In 2002 and 2003, researchers ...
Cached Medicine News:Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 2Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 3Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 4Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 2Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 3Health News:Better care for dementia patients through new funding 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Edwards Lifesciences' Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan 2Health News:Better-Educated Smokers More Likely to Quit After Seeing Ads 2
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
Medicine Products: